Oda et al. reported that serum levels of CXCL10 of DM-ILD patients at 2 weeks after treatment initiation were significantly higher in the death group, and the change ratio of serum levels of CXCL10 and CXCL11 was higher in the death group, suggesting that serum levels of CXCL10 may be possible biomarkers of disease activity and prognosis in DM-ILD (Oda et al., 2017). Here, CXCL11 is linked to dermatomyositis.